New and Innovative Approaches to Laboratory Diagnosis of Zika, Dengue and other Arboviruses
May 2-4, 2017 - Les Pensières Center for Global Health, Veyrier du Lac, France
The aim of the Partnership for Dengue Control (PDC) is to cast a wider net to facilitate and expedite urgently needed technology development, both for research and to be rolled out in countries affected by arboviral diseases.
This workshop was organized, therefore, by the PDC and the Mérieux Foundations, with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur. Its purpose was to identify the gaps in the diagnosis of these viral infections, to review the new technological innovations that may be available to fill those gaps and to promote and develop mechanisms for accelerating the pathway from tool development to impact.
The driving force behind the event was the critical need for more sensitive, specific and accurate diagnostic tests to support more effective surveillance and prevention and to halt the increased frequency and magnitude of epidemics and the higher incidence of severe disease outcomes caused by Zika, dengue and other arboviral infections.
Key insights emerged to the 3 questions posed during the workshop:
Where are where are we now?
- Diagnostic methods to detect DENV and ZIKV infections are still mainly laboratory-based and require further clinical evaluations,
- Few validated assays are available on the market to differentiate ZIKV from other flavivirus infections,
- Diagnostics that can be used at or near the point-of-patient care (POC) to detect and discriminate between the different flaviviral infections are needed.
Where do we go?
- Towards specific molecular, serological, antigen-based and combination assays to identify and differentiate co-circulating flaviviral infections at or near POC, as well as for surveillance, in the intermediate and long-term future.
How do we make it happen?
- Identify and address challenges: uncoordinated efforts, lack of funding mechanisms, limited access to well-characterized clinical samples, lack of definition of evaluation methods and sites, lack of regulatory harmonization, market opacity, low guarantee of return on investment (ROI), as well as slow and fragmented pathway to implementation,
- Offer solutions: establish early partnerships and promote information sharing, facilitate access to samples and standardized protocols, promote regulatory harmonization, define priorities and build diagnostic preparedness strategies.
Approximately 80 people attended the event including participants from academia, industry, NGOs, UN agencies (including WHO), investor organizations, policy makers and regulatory bodies. A full report has been published and includes a full list of participants and a summary of all the presentations, comments and strategies that resulted from the 3-day event.
Tuesday, May 2 – Day 1
Where are we now?
Chairs: Annelies Wilder-Smith, Duane Gubler
Chairs: Francis Moussy, Amy Lambert
Wednesday, May 3 – Day 2
Where do we go? Technological innovations in Flavivirus diagnostics
|Session 3: Detecting acute infection
Chairs: Maurine Murtagh, Arlene Chua
|Session 4: Detecting past infections
Chairs: Eva Harris, Aravinda de Silva
|Dx antigen discovery and imminent technological innovations
|Cutting Edge Innovations For The Intermediate And Long-Term Future
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
|Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response
Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
|Session 6: Critical steps to ensure quality products
Chairs: Rosanna Peeling, Piero Olliaro
|Session 7: Identifying PDC’s roles to support innovative diagnostics
Chairs: May Chu, Julie Schäfer